Healthcare

As the Healthcare sector emerges from a time of immense pressure and high visibility, we see huge investment, potential and opportunity ahead

Truly dynamic and innovative at its core, Healthcare is poised for a period of growth and transformation. Driven by a range of factors – including Covid-19; greater emphasis on personalisation; digitisation and technological innovation; changing demographics; and shifting customer and patient expectations – organisations of all sizes and ownership structures seek the right leaders to seize this opportunity.

Supporting clients at Board, Executive Committee and leadership levels, we combine extensive experience in and a deep understanding of the wide and varied Healthcare sector, including its clinical leadership, as well as access to relevant talent pools in adjacent consumer-facing industries.

View current opportunities

The MBS Group acts as an advisor to NHS and other public sector bodies on senior appointments. To view current appointments, click here.

Our Experience

Clinical Services
HealthTech & Digital Healthcare
Healthcare Systems
Life Sciences
Insurers
Medical Devices & Diagnostics

Selected Clients

Key People

Hatty Cadman

Hatty Cadman

Partner

Moira Benigson

Moira Benigson

Founder & Chair

Elliott Goldstein

Elliott Goldstein

Managing Partner

Latest MBS News & Intelligence

MBS News

26 April 2024 - 8:20

Voyage Care expands healthcare portfolio Voyage Care, which supports more than 3,500 people in the UK with learning disabilities, autism and brain injuries, has announced the acquisition of Cristal Care and Newfound Care. Together, the acquisitions represent seven care homes. Read more.


25 April 2024 - 8:25

Align Tech lifts annual sales forecast The maker of teeth aligners has topped Wall Street estimates for first-quarter profit growth, after resilient demand for its products from teenagers and younger patients. The company now expects full-year revenue growth to be between 6% and 8%. Read more.


25 April 2024 - 8:17

Quarterly revenue up at AstraZeneca The FTSE 100 drug giant has said that sales rose by a better-than-expected 19% to $12.6bn in the first three months of the year. The company has attributed its strong results to a rise in oncology revenue. Read more.